SCHEMBL923800

SCHEMBL923800

COC(=O)c1cc(C2CCCCO2)c(=O)n(C2CCCC2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 8/20 0.43
SMN1; SMN2 Q16637 4/20 0.43
NPSR1 Q6W5P4 3/20 0.43
ATM Q13315 1/20 0.43
CFTR P13569 1/20 0.41
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
RAB9A P51151 1/20 0.39
MAPK1 P28482 1/20 0.38
KMT2A Q03164 3/20 0.36
MEN1 O00255 2/20 0.36
MAPT P10636 2/20 0.35
POLB P06746 2/20 0.35
LMNA P02545 1/20 0.35
PKM P14618 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
ALOX15 P16050 2/20 0.35
HSD17B10 Q99714 1/20 0.35
HNF4A P41235 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL924171 0.85 HSD17B10 (0.42) ALDH1A1NPC1HPGDRAB9AKMT2A
SCHEMBL925293 0.76 SMN1; SMN2 (0.53) ALDH1A1SMN1; SMN2NPSR1ATMKMT2A
SCHEMBL925273 0.76 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2NPSR1ATMHPGD
SCHEMBL924486 0.75 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2NPSR1ATMHPGD
SCHEMBL925284 0.73 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2NPSR1ATMNPC1
SCHEMBL925968 0.73 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2NPSR1ATMHPGD
SCHEMBL924612 0.72 ALDH1A1 (0.43) ALDH1A1SMN1; SMN2NPSR1ATMHPGD
SCHEMBL924151 0.72 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2NPSR1ATMNPC1
SCHEMBL26000144 0.72 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2NPSR1ATMNPC1
SCHEMBL31401053 0.71 HPGD (0.50) ALDH1A1SMN1; SMN2NPSR1ATMCFTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163766-B2 Beta-secretase modulators and methods of use AMGEN INC. (US) 2012-04-24 US disclosed
US-20110118250-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-05-19 US disclosed
US-7872009-B2 Beta-Secretase modulators and methods of use AMGEN INC. (US) 2011-01-18 US disclosed
US-20070185103-A1 Beta-secretase modulators and methods of use AMGEN INC. 2007-08-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118250-A1 BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP ALDH1A1 2087/4885SMN1; SMN2 1434/4885NPSR1 1471/4885
US-20070185103-A1 Beta-secretase modulators and methods of use BACE1, BACE2, APP ALDH1A1 2087/4885SMN1; SMN2 1434/4885NPSR1 1471/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.